GlassScriptPhysician profile
Amanda Carson-Griffin
NPI 1124456850
$574.84
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $575.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $293.30 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.08 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.89 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $61.71 | 2021 | |
| Alkermes, INC. | $43.11 | 2021 | |
| Vanda Pharmaceuticals INC. | $20.03 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.72 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Carson-Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.